feed,title,long_url,short_url
Benzinga,"Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues",https://benzinga.com/general/biotech/24/08/40316248/ascendis-hypoparathyroidism-drug-scores-fda-approval-as-first-and-only-treatment-replacing-takeda,https://da.gd/EBl2C
